VPT Profile - Equity Insider

⁠VentriPoint Diagnostics (TSXV:VPT)

NEWS

Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement

Toronto, Ontario, May 22, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the“Corporation”) (TSXV:VPT) is pleased to announce the closing of a non-brokered private placement of 2,800,273 units (each, a “Unit”) at a price of $0.11 per Unit for aggregate gross proceeds of $308,030 (the “Offering”), subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) common share (“Common Shares”) of the Corporation, and one (1) common share purchase warrant (“Warrants”).

Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 for a period of 24 months from the closing of the Offering. The Corporation will use the proceeds of the Offering to fund sales and marketing initiatives, operational costs and general working capital. No finders’ fees were paid related to the Offering.

The Offering is a related party transaction within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI-61-101”) as an insider of the Corporation subscribed for 136,364 Units on the same terms as arm’s length subscribers. The Corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the Corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25% of the market capitalization of the Corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2,500,000. The Corporation did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Offering, which the Corporation deems reasonable in the circumstances in order to complete the transaction.

All securities issued and issuable pursuant to the Offering will be subject to a hold period of four months plus one day from the date of closing of the Offering. The Offering is subject to approval by the Exchange.

The securities offered will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent a registration statement or an applicable exemption from the registration requirements. The press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard
and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Corporation’s most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors is not exhaustive. The forwardlooking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology

For Immediate Release

Toronto, Ontario – The Newswire – May 4, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12– 16, 2026 in Padua, Italy.

Founded in 1963, AEPC is the world’s largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries and beyond. Its members are united by a commitment to advancing the practice of congenital and paediatric cardiology and improving outcomes for patients with heart disease.

This year’s meeting is hosted by the University of Padova – one of the world’s oldest and most prestigious institutions – and features a scientific program centred on advanced cardiovascular imaging and artificial intelligence. These are areas where Ventripoint is driving meaningful clinical progress.

Ventripoint will exhibit alongside its European distributor, AngioPro, welcoming existing customers and engaging with clinicians from the global congenital cardiology community. A key focus at the booth will be the power of supporting evalution of cardiac function over time of congenital heart disease (CHD) patients using VMS+™. The importance of this approach is underscored by the 2020 ESC Guidelines for Adult Congenital Heart Disease – co-endorsed by AEPC – which identify CHD as a lifelong chronic condition requiring structured, individualised follow-up, and affirm echocardiography as the key modality for longitudinal assessment of ventricular function (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554)

Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients. The latest release, VMS+™ 4.0, was purpose-built around the needs of clinicians – streamlining workflows, reducing the time required to generate assessments, and making advanced cardiac analysis accessible at the point of care. At the point of a patient’s first echocardiogram, VMS+™ provides accurate volumetric cardiac measurements equivalent to MRI – detailed insights that arrive early in the care journey, supporting clinical decision-making and more effective patient management across a lifetime of care.

“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard
and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Forward Looking Statements

Ventripoint Issue Shares for Payment of Debenture Interest

Toronto, Ontario, April 22, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“TSXV”) approval. The Corporation will issue an aggregate of 555,699 common shares (“Shares”) for the payment of an aggregate of $61,217 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on September 20, 2024, March 21, 2025, September 2, 2025, and October 14, 2025. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.11, subject to the approval of TSXV, and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.

About Ventripoint Diagnostics Ltd.

For further information, please contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Forward Looking Statements

Ventripoint’s VMS™ + 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential

Toronto, Canada – April 20, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSX-V:VPT, OTC:VPTDF), is proud to announce that its proprietary VMS+™ 4.0 (Ventripoint Medical System) technology has been awarded a Gold Medal at the 2026 Edison Awards in the Precision Health Technologies sub-category.

The Edison Awards are widely regarded as one of the most prestigious global recognitions for innovation. Judged by a peer review panel of senior executives, clinicians, engineers, and technology leaders, Gold awards are reserved for innovations that demonstrate not only technical excellence, but clear differentiation, market readiness, and the potential for sustained real-world impact. For investors, this recognition represents independent validation of Ventripoint’s strategic direction and technological leadership.

At the 2026 Edison Awards two luminaries were recognized: artist Rhianna for her philanthropy, and NBA Commissioner Adam Silver for his role in sports innovation. With its receipt of the Gold Award Ventripoint joins a peer group that includes Viz.ai, Heartflow, Abbott, Medtronic and Boston Scientific in what is described as “the Oscars of Innovation”.

Independent Validation of a Breakthrough Platform

VMS™ + 4.0 was recognised for its ability to transform standard 2D echocardiograms into highly accurate, reproducible 3D models of the heart—delivering volumetric and functional measurement traditionally accessible only through cardiac MRI. By combining 2D echocardiogram with Ventripoint’s patented Knowledge-Based Reconstruction and artificial intelligence assistance, VMS™ + 4.0 provides accurate volumetric cardiac measurements equivalent to MRI.at a fraction of the cost, time, and infrastructure burden.

Importantly, this award reflects more than innovation in theory. Edison Award evaluators place strong emphasis on technologies that are already deployed, clinically validated, and delivering measurable benefits. VMS+™ 4.0 is currently in use at major hospitals across Europe, the United Kingdom, the United States, and Canada—demonstrating both clinical relevance and commercial scalability.

“The Edison Awards recognize innovations that have moved beyond promise into real-world impact. Being awarded Gold affirms that VMS™ 4.0 has reached that threshold, and reinforces our belief that our platform has significant room to grow as adoption accelerates and new applications emerge”, sated Hugh MacNaught, President
& CEO of Ventripoint Diagnostics Ltd.

Why This Matters

This Gold Edison Award reinforces three critical fundamentals:

1. Technology Leadership

VMS+™ has been recognized at a global level as best-in-class within precision health technologies. This external endorsement underscores Ventripoint’s position at the forefront of AI-enabled cardiac diagnostics, in a market increasingly prioritizing accuracy, speed, and cost efficiency.

2. Market Readiness and Adoption

Unlike early-stage experimental technologies, VMS+™ 4.0 is already embedded within clinical workflows. The Edison Awards explicitly prioritize innovations that have advanced beyond pilot status and into real-world adoption—an important signal of reduced execution risk and accelerating commercial momentum.

3. Platform Potential Beyond Today’s Use Cases

While VMS+™ 4.0 is currently focused on cardiac chamber quantification and function, its core architecture is inherently extensible. The recognition highlights not just what the platform delivers today, but what it enables tomorrow: broader indications, longitudinal monitoring, decentralized diagnostics, and integration into value-based care models.

A Technology Built for a Changing Healthcare System

Healthcare systems globally are under pressure to deliver higher diagnostic precision with fewer resources. MRI capacity constraints, long wait times, and high costs continue to limit access—particularly in paediatric, rural, and emerging-market settings. VMS+™ 4.0 directly addresses these structural challenges by enabling high-quality cardiac assessment at the point of care.

The Edison Award recognition affirms that Ventripoint’s technology aligns with macro-level healthcare trends: decentralization, AI-assisted decision support, and scalable precision medicine. These dynamics create the foundation for long-term demand growth rather than one-time product cycles.

Momentum That Extends Beyond the Award

Awards alone do not define value creation—but they often precede it. The Edison Award serves as a powerful signal to hospital systems, strategic partners, regulators, and payors that VMS™ represents a validated, trusted, and forward-looking solution within cardiac care.

For Ventripoint, this recognition strengthens the company’s ability to:
• Accelerate enterprise-level hospital deployments
• Deepen clinical and research partnerships
• Support reimbursement and procurement discussions
• Expand internationally with enhanced credibility

Most importantly, it reinforces a long-term vision: building a durable, scalable diagnostics platform that continues to compound clinical relevance and commercial opportunity over time.

Looking Ahead

The Gold Edison Award marks a significant milestone—but not a destination. Ventripoint remains focused on execution: expanding market penetration, advancing the capabilities of VMS+™ 4.0, and unlocking additional value from a technology platform that has now been independently recognized as leading-edge.

This award represents affirmation that Ventripoint is not only solving an important clinical problem today, but is positioned to go further—scaling impact, extending platform value, and participating meaningfully in the future of precision healthcare.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS+™ products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+™ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

For further information, please contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forwardlooking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group

Partnership to explore expanded cardiac screening, clinical research, and AI-assisted echocardiography in Costa Rica

Toronto, Ontario – April 1, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging solutions, today announced a collaboration with the Health Division of the Montecristo Group to explore new clinical pathways for the implementation of Ventripoint’s VMS+™ cardiac imaging platform in Costa Rica.

The collaboration will focus on identifying opportunities to expand access to advanced cardiac diagnostics, including remote screening for congenital and structural heart disease, the integration of VMS+™ technology into clinical research and clinical trial programs, and broader deployment of VMS+™ AI-assisted echocardiography solutions for patients across Costa Rica. These initiatives aim to improve accuracy in heart monitoring while increasing access to modern diagnostic tools for both public and private healthcare
systems.

Through this partnership, the organizations will explore how the VMS+™ system can support hospitals, physicians, and research organizations by assisting the accuracy of cardiac imaging and enabling earlier detection of heart conditions, particularly in underserved or remote communities.

“We are excited to collaborate with the Health Division of the Montecristo Group to enable the adoption of VMS+™ technology in Costa Rica,” said Hugh MacNaught, President & CEO of Ventripoint Diagnostics. “Their strong healthcare network, commitment to affordable high-quality care, and passion for innovation make them an ideal partner as we work to expand access to advanced cardiac diagnostics and support clinical research opportunities in central America.”

“At the Metropolitano Research Institute, we are proud to serve as the research partner of Ventripoint Diagnostics in Costa Rica, leveraging our expertise in clinical research execution and large-scale screening deployment in Costa Rica. This partnership enables us to translate advanced AI-driven cardiac imaging into real-world impact by expanding early detection, improving diagnostic accuracy, and increasing access to high-quality cardiovascular care.” Catalina Ulloa, Director, Metropolitano Research Institute, Hospital Metropolitano, Grupo Montecristo.

The collaboration is expected to support research partnerships, technology deployment initiatives, and clinical trial (CRO) programs that incorporate VMS+ as an affordable advanced cardiac measurement tool that supports new care models and pathways.

About the Health Division of the Montecristo Group

The Health Division of the Montecristo Group is part of one of Costa Rica’s leading corporate groups, focused on advancing healthcare access, innovation, and patientcentered medical services. Through a network of healthcare companies and medical facilities – including Hospital Metropolitano and other specialized health services – the division works to provide high-quality medical care, promote preventative health, and introduce innovative healthcare solutions that improve wellbeing for communities across Costa Rica and the region. (grupomontecristo.com)

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Ventripoint Partners with First Light Health to Bring AI-Powered Cardiac Diagnostics to Indigenous and Remote Communities

Landmark partnership deploys hub-and-spoke model to close the cardiac care gap for Indigenous and underserved populations in British Columbia — with national and global expansion planned.

Toronto, Ontario (March 17, 2026) – Ventripoint Diagnostics Ltd. (” Ventripoint “, “ VPT ” or the ” Company “), (TSXV:VPT; OTC:VPTDF) a leader in AI-assisted cardiac imaging, today announced a partnership with First Light Health (“FLH”) to extend life-saving heart diagnostics to Indigenous and remote communities that have long faced barriers to specialist cardiac care. The collaboration marks a pivotal milestone in Ventripoint’s mission to make advanced, accurate cardiac imaging universally accessible – regardless of geography.

The partnership operates on a “hub-and-spoke” model: a central hub with advanced cardiac capabilities supports a network of connected sites in smaller, remote, and Indigenous communities. Using Ventripoint’s VMS+™ system, local healthcare providers can capture and enhance ultrasound scans on-site, then transmit them digitally to hub specialists for rapid interpretation and consultation – eliminating the need for patients to travel hundreds of kilometres for basic cardiac assessments.

FLH will be a key delivery partner within this expanding network, anchored by operations in Vancouver. From there, FLH will extend services to remote communities across British Columbia, Yukon, Alberta, Manitoba, and New Brunswick. The impact of the model is straightforward:

Indigenous and non-Indigenous patients alike receive advanced cardiac imaging in their own communities – without long-distance travel, prohibitive costs, or months-long wait times. For communities where cardiovascular disease disproportionately affects outcomes, timely access to accurate diagnostics can be the difference between early intervention and preventable harm.

Central to this model is Ventripoint’s VMS+™ system, which achieves MRI-level cardiac measurement accuracy by converting standard 2D echocardiograms into precise 3D volumetric images – at a fraction of the cost and time of an MRI. Already deployed across multiple countries, VMS+™ is used to support the diagnosis and monitoring of cardiac conditions. Publications from users include studies covering a range of cardiac indications including congenital heart disease, heart failure, pulmonary hypertension, and chemotherapy-related cardiac complications.

“Cardiovascular disease doesn’t respect geography – but too often, access to cardiac care does,” said Hugh MacNaught, CEO of Ventripoint. “Our work with First Light Health and other First Nations partners such as the Nisg ̱ a’a Valley Health Authority demonstrates the need for a made-in-Canada innovation that can close that gap. We see the potential for this solution to be widely deployed – from the Arctic to the Amazon. This is what scalable, equitable heart care looks like.”

Dr. Ripenjot Rai, Medical Director, “At First Light Health, our mission is to help close long-standing gaps in access to care while advancing reconciliation through meaningful partnerships and responsible private enterprise. By combining innovative technologies with culturally safe, trauma-informed care models, we can bring advanced diagnostics and clinical expertise closer to the communities that need them most. Collaborations like this help ensure patients in Indigenous and remote communities receive timely, high-quality care while remaining connected to their communities.”

Ventripoint is actively expanding this hub-and-spoke model across Canada and into international markets where VMS+ is approved for use with the goal of ensuring that every patient – wherever they live – has access to the highly accurate cardiac diagnostics.

About Ventripoint Diagnostics Ltd.

Ventripoint is a Toronto-based medical technology company and industry leader in the application of artificial intelligence to echocardiography. Its flagship VMS+™ product line is powered by proprietary Knowledge Based Reconstruction technology — the result of over a decade of development — delivering volumetric cardiac measurements with accuracy equivalent to MRI.

Approved for use in the U.S., Canada, and Europe, VMS+™ works with ultrasound systems from any vendor, making gold-standard cardiac imaging accessible and affordable for clinicians and patients worldwide.

First Light Health

First Light Health (“FLH”) is an Indigenous-owned healthcare company dedicated to improving access to high-quality medical services while advancing reconciliation through socially responsible private enterprise. The organization develops and supports innovative healthcare models that bring advanced diagnostics, clinical services, and medical expertise closer to Indigenous and remote communities across British Columbia and the Yukon.

Grounded in principles of cultural safety and trauma-informed care, First Light Health works collaboratively with communities and health providers to design services that respect Indigenous values, traditions, and community priorities. In addition to developing clinical infrastructure and care programs, FLH provides medical oversight, governance, and strategic direction for healthcare initiatives and private sector partners seeking to deliver equitable health services.

Through these efforts, First Light Health aims to reduce barriers to care, improve health outcomes, and build sustainable healthcare solutions that support long-term community wellness.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint Issues Shares for Payment of Debenture Interest and Reports on Debenture Conversions

Toronto, Ontario, March 4, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ TSXV ”) and issued of 291,344 common shares (“ Shares ”) for the payment of an aggregate of $36,989.01 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on June 28, 2024, December 16, 2024, January 17, 2025, and February 7, 2025. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.127, and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.

The debentures issued January 17, 2025 and February 7, 2025, an aggregate of $256,000, have been converted and so no further interest is owing on these series of debentures.

About Ventripoint Diagnostics Ltd.

This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Factors which could materially affect such forward-looking information are described in the risk factors in the Corporation’s most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR+ at www.sedarplus.ca.

Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint Diagnostics Ltd. Signs Commercial Agreement with LG Consulting Solutions to Support VMS+ Deployment in Northern California

Toronto, Ontario, March 3, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) today announced the signing of a Memorandum of Understanding and consulting agreement with LG Consulting Solutions to support commercialization and deployment of the VMS+™ system in the Northern California region.

Under the agreement, LG Consulting Solutions will provide economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting Ventripoint’s VMS+™ technology.

The collaboration will focus on demonstrating the economic and clinical value of AI-enhanced echocardiography imaging and workflow integration across healthcare systems in the region, including Sacramento and San Francisco.

As part of the agreement, LG Consulting Solutions is purchasing a VMS+™ system for deployment as a demonstration and implementation platform to support hospital engagement, clinician training, and economic value assessments within targeted healthcare institutions.

The agreement includes consulting services related to outcomes evaluation, implementation planning, and ongoing operational support. The collaboration is designed to help healthcare providers better understand the clinical and economic impact of cardiac assessment using the VMS+™ system.

“Economic and operational clarity are critical to accelerating the adoption of new medical technologies,” said Hugh MacNaught, President and CEO of Ventripoint.

“This collaboration will help hospitals clearly evaluate how VMS+™ can improve cardiac care pathways, enhance clinical insight into cardiac function, and support better patient care while delivering measurable value to healthcare systems.” Lori Gallian, Principal of LG Consulting, added:

“Healthcare systems increasingly require clear clinical and economic evidence before adopting new technologies. Through this collaboration, we will work directly with cardiac programs to develop practical implementation strategies and demonstrate how VMS+ ™can deliver both clinical and operational benefits.” The agreement also includes the potential for revenue sharing related to 3D echocardiography processing services associated with accounts supported by the consulting engagement.

Northern California represents an important market for Ventripoint given its concentration of leading cardiac centers and healthcare systems focused on improving cardiovascular outcomes and operational efficiency.

About LG Consulting Solutions

LG Consulting Solutions brings nearly a decade of established relationships and on-the-ground experience within the hospital networks they serve. The consultancy’s approach is built on something the healthcare industry doesn’t always slow down for – listening. By genuinely hearing what clinicians need, how they work, and what earns their trust, LG Consulting Solutions bridges the gap between innovative technology and real-world clinical adoption. Their work is rooted in connection first, integration second, and the belief that the best outcomes happen when healthcare providers feel heard before they’re asked to change.

About Ventripoint Diagnostics Ltd.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Ventripoint Provides Corporate Update and Announces Shareholder Video Conference Call

Toronto, Canada – February 19, 2026 – Ventripoint Diagnostics Ltd. (” Ventripoint ” or the ” Company “) ( TSXV:VPT; OTC:VPTDF ), a leading provider of innovative AI-powered cardiac diagnostic solutions, is pleased to provide a corporate update and announces a shareholder videoconference call.

Dear Shareholders ,

Ventripoint continues to execute on its strategy to expand commercialization of VMS+™, strengthen clinical adoption, and position the Company for revenue growth.

Key Achievements and Advances Since the Last Shareholder Call

Since our last shareholder call, the Company has made progress across regulatory execution, commercialization planning, clinical engagement, and operational readiness, including:

Commercial and Market Development

• Continued refinement of the Company’s U.S. go-to-market approach, designed to reduce friction in the sales process and accelerate adoption

• Ongoing engagement with prospective customers through virtual demonstrations and pipeline development activities

• Continued alignment with distributors and partners in Europe and the United Kingdom to advance near-term opportunities

Partnerships and Strategic Initiatives

• Continued constructive work with ASCEND Cardiovascular toward integration discussions and commercial alignment

• Ongoing collaboration with the Ollie Hinkle Heart Foundation, supporting U.S. system placement opportunities

• Continued collaboration with Lishman Global to support manufacturing and regulatory preparation activities in China to enable market entry

• Continued evaluation of potential distribution and strategic opportunities in Asia, including active discussions with a family office group

• Continued development of strategy and early engagement efforts to expand VMS+™ into valvular and structural heart applications

Technology, Product, and Regulatory

• Continued execution on commercialization activities for VMS+™ v4.0, including customer upgrade readiness and clinical workflow integration planning

• Expanded internal focus on training, installation, and customer support systems, including development of scalable training materials and videos

• Strengthened internal processes supporting quality and manufacturing readiness, building on prior successful audits

• Continued progress on improving connectivity and integration workflows to support adoption into routine clinical practice

Corporate Development and Team Expansion

• Continued engagement with experienced commercial professionals, including individuals positioned to transition into expanded roles upon completion of financing

• Continued engagement with governance-level candidates to strengthen board and advisory capacity in commercialization and capital markets

Capital Markets and Financing

• Continued advancement of financing initiatives designed to secure growth capital while maintaining disciplined dilution management

• Continued engagement with capital markets advisors and investor awareness partners to broaden visibility of the Company and its opportunity

Shareholder Call Details

The Company will host a shareholder update call to provide additional context on recent developments, commercialization priorities, and upcoming milestones.

Shareholder Videoconference:

Date: Thursday February 26, 2026

Time: 1pm EST

Zoom Link: https://us02web.zoom.us/j/83809648859?pwd=WsxhF4PWpwlTSjTUxsbbffsbIaIJIb.1 Meeting ID: 838 0964 8859

Passcode: 893160

Dial-in Numbers:

Dial by your location

• +1 438 809 7799 Canada

• +1 587 328 1099 Canada

• +1 647 558 0588 Canada

• +1 778 907 2071 Canada

• +1 780 666 0144 Canada

• +1 346 248 7799 US (Houston)

• +1 646 558 8656 US (New York)

• +1 669 900 9128 US (San Jose)

• +1 253 215 8782 US (Tacoma)

• +1 301 715 8592 US (Washington DC)

• +1 312 626 6799 US (Chicago)

Meeting ID: 838 0964 8859

Passcode: 893160

Find your local number: https://us02web.zoom.us/u/kbnEnDZXPT Closing Comments

Ventripoint continues to advance its commercialization strategy while building the operational foundation required to support adoption and growth. The Company appreciates the continued support of its shareholders and looks forward to providing further updates during the call.

Sincerely,

Hugh MacNaught

President & CEO hmacnaught@ventripoint.com

(604) 671-4201

About Ventripoint Diagnostics Ltd.

Ventripoint is a leader in the application of AI (Artificial Intelligence) to echocardiography.

Ventripoint’s VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients.

Providing better care to patients serves as a springboard and basic standard for all Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Forward Looking Statements

Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Ventripoint Issues Shares for Payment of Debenture Interest and Reports on Debenture Conversions

Toronto, Ontario, February 11 , 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“ TSXV ”) approval. The Corporation will issue an aggregate of 291,344 common shares (“ Shares ”) for the payment of an aggregate of $36,989.01 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on June 28, 2024, December 16, 2024, January 17, 2025, and February 7, 2025. The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of $0.127, subject to the approval of TSXV, and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.

The debentures issued January 17, 2025 and February 7, 2025, an aggregate of $256,000, have been converted and so no further interest is owing on these series of debentures.

About Ventripoint Diagnostics Ltd.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Ventripoint Issues Shares for Debt Settlement and Awards Option Grants

Toronto, Ontario, January 28, 2026 – Ventripoint Diagnostics Ltd. (” Ventripoint ” or the ” Corporation “, TSXV:VPT) is pleased to announce that it received approval from the TSX Venture Exchange (“ TSXV ”) and has issued 4,276,964 common shares (the “ Shares ”) of the Corporation to settle an aggregate of $427,696.35 of debt owed to certain arm’s length creditors of the Corporation at a price of $0.10 per share.

The Shares are subject to a hold period of four months and one day. The Corporation determined to satisfy the indebtedness with Shares in order to preserve its cash for development of its business.

The Company has also issued option grants on January 20, 2026, the Corporation granted an aggregate of 2,516,500 options to directors, officers, employees, contractors and consultants of the Corporation with an exercise price of $0.12 and terms of between 2 (two) to 10 (ten) years, vesting from immediately to over a 3 (three) year period. Of these option grants, 200,000 were awarded to directors and an additional 1,300,000 were awarded to officers some of which are also directors of the Corporation.

These annual option grants are an important part of incentivizing stakeholders to drive value in the Corporation.

Since the last update (see NR June 17, 2025), a total of 780,000 options were exercised with a weighted average price of approximately $0.105 per share for gross proceeds to the Corporation of $81,800.00. There are currently 16,683,500 option grants outstanding with exercise prices between $0.10 to $0.50 with a weighted average price of $0.17, and 14,555,167 of these option grants have vested.

The Corporation has approximately 2.0 million options available for future grants under the Stock Option Plan as approved by shareholders at the last Special and Annual General Meeting of the Corporation.

About Ventripoint Diagnostics Ltd.

addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Ventripoint Announces Closing of Non-Brokered Units Private Placement

Toronto, Ontario, January 19, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces the closing of its previously announced non-brokered private placement (see press release of December 30, 2025) of an aggregate of 10,097,720 units (each, a “ Unit ”) at a price of $0.10 per Unit for aggregate gross proceeds of $1,009,772 (the “ Offering ”). Directors and Officers of the company (insiders) invested an aggregate of $139,340, which was 13.8% of the total proceeds.

Each Unit is comprised of one (1) common share (“ Common Shares ”) of the Corporation, and one (1) common share purchase warrant (“ Warrants ”). Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.13 for a period of 24 months from the closing of the Offering. The Corporation reserves the right to accelerate the Warrant expiry period upon 30-day’s notice if the Common Shares traded at or above $0.26 for a period of 10 consecutive days, including days where no trades occur.

The Corporation has paid cash finder’s fees of $15,600 and issued common share purchase warrants (“ Finder’s Warrants ”) to purchase an aggregate of 156,000 shares of the Company. Each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CDN$0.13 per Common Share for a period of 24 months from the closing of the Offering.

The Offering is a related party transaction within the meaning of TSXV Policy 5.9 and Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI-61-101”) as certain insiders of the Corporation subscribed for an aggregate of 1,393,400 of Units on the same terms as arm’s length subscribers. The Corporation is relying on exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and (b) and 5.7(a) and (b) of MI 61-101, as the Corporation is not listed on a specified market and the fair market value of the participation in the transactions by insiders does not exceed 25% of the market capitalization of the Corporation, as determined in accordance with MI 61-101 and the fair market value of the transactions is not more than $2,500,000. The Corporation did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Offering, which the Corporation deems reasonable in the circumstances in order to complete the transaction.

The Corporation will use the proceeds of the Offering to fund operational costs related sales and marketing, additional key personnel, and general working capital purposes.

About Ventripoint Diagnostics Ltd.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Ventripoint Doubles the Size of Private Placement Due to Strong Investor Demand

Toronto, Ontario, January 7, 2026 — Ventripoint Diagnostics Ltd. (Ventripoint or the Corporation, TSXV:VPT), a leading innovator in AI-powered cardiac imaging technology, today announced, in response to significant investor interest, it will double its previously announced non-brokered private placement (“ Offering ”) (See press release December 30, 2025) from $500,000 to $1,000,000 subject to TSX Venture Exchange (“ TSXV or the Exchange ”) approval.

Each Unit will be comprised of one (1) common share (“ Common Shares ”) of the Corporation, and one (1) common share purchase warrant (“ Warrants ”).

Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.13 for a period of 24 months from the closing of the Offering. The Corporation reserves the right to accelerate the Warrant expiry period upon 30 days notice, if the Common Shares trade at $0.26 or above on the TSXV for a period of 10 consecutive days, including days where no trades occur.

The Corporation may pay cash finder’s fee and issue common share purchase warrants (“ Finder’s Warrants ”) of up to 8% of the gross proceeds of the Offering.

Each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CDN$0.13 per Common Share for a period of 24 months from the closing of the Offering.

The Corporation will use the proceeds of the Offering to support critical commercialization activities, manufacturing scale-up, continued regulatory submissions, and operational requirements.

About Ventripoint Diagnostics Ltd.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

result of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint Issues Shares for Debt Settlement and Awards Option Grants

Toronto, Ontario, January 28, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) is pleased to announce that it received approval from the TSX Venture Exchange (“TSXV”) and has issued 4,276,964 common shares (the “Shares”) of the Corporation to settle an aggregate of $427,696.35 of debt owed to certain arm’s length creditors of the Corporation at a price of $0.10 per share. The Shares are subject to a hold period of four months and one day. The Corporation determined to satisfy the indebtedness with Shares in order to preserve its cash for development of its business.

Since the last update (see NR June 17, 2025), a total of 780,000 options were exercised with a weighted average price of approximately $0.105 per share for gross proceeds to
the Corporation of $81,800.00. There are currently 16,683,500 option grants outstanding with exercise prices between $0.10 to $0.50 with a weighted average price of $0.17, and 14,555,167 of these option grants have vested.

About Ventripoint Diagnostics Ltd.

For further information, please contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Forward Looking Statements

Ventripoint Announces Non-Brokered Units Private Placement

Toronto, Ontario, December 30, 2025 – TheNewswire – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces a non-brokered private placement of up to 5,000,000 units (each, a “ Unit ”) at a price of $0.10 per Unit for aggregate gross proceeds of up to $500,000 (the “ Offering ”) subject to TSXV Venture Exchange (the “ Exchange ”) acceptance. Each Unit will be comprised of one (1) common share (“ Common Shares ”) of the Corporation, and one (1) common share purchase warrant (“ Warrants ”).

Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.13 for a period of 24 months from the closing of the Offering. The Corporation reserves the right to accelerate the Warrant expiry period upon 30 days notice if the Common Shares trade at $0.26 for a period of 10 consecutive days, including days where no trades occur.

The Corporation may pay cash finder’s fee and issue common share purchase warrants (“ Finder’s Warrants ”) of up to 8% of the gross proceeds of the Offering. Each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CDN$0.13 per Common Share for a period of 24 months from the closing of the Offering.

The Corporation will use the proceeds of the Offering to fund operational costs related sales and marketing, additional key personnel, and general working capital purposes.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS+ products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Factors which could materially affect such forward-looking information are described in the risk factors in the Corporation’s most recent annual management’s discussion and

analysis that is available on the Corporation’s profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint Diagnostics Announces Collaboration with Summit Sciences

Toronto, Ontario (December 18, 2025) – Ventripoint Diagnostics Ltd. (” Ventripoint ” or the ” Company “), (TSXV:VPT; OTC:VPTDF) a leader in AI-enhanced cardiac imaging solutions, today announced the engagement of Dana Friesen and Summit Sciences, a specialized consulting firm, to create more sophisticated, customer-centric financial and return-on-investment (ROI) models. This strategic partnership aims to equip healthcare providers with enhanced tools to evaluate the economic benefits of adopting Ventripoint’s innovative VMS+ technology for cardiac diagnostics.

The collaboration will focus on refining financial modeling frameworks that highlight the cost savings, operational efficiencies, and clinical outcomes associated with Ventripoint’s AI-driven 3D heart modeling system. By integrating advanced analytics and real-world data, the new models will provide tailored insights for hospitals, clinics, and cardiology practices, demonstrating clear ROI through process improvement, better accuracy in heart assessments, and optimized resource allocation.

“We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities,” said Hugh MacNaught, President & CEO of Ventripoint Diagnostics. “Dana’s extensive expertise in healthcare transformation, combined with Summit Sciences’ proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide.”

“We believe that Ventripoint’s VMS+ system can provide real benefits to patients, healthcare providers, and payors,” commented Dana Friesen, CEO of Summit Sciences. “By creating new models based on real-world data, Ventripoint will be able to accelerate the pace of commercializing VMS+ while expanding global access to advanced cardiac imaging. Our history of working in partnership with a variety of partners and delivery models, including indigenous health networks and community-based models of care across Canada, the United States, and Latin America provides experience in delivering culturally sensitive and appropriate solutions addressing cost effectiveness and local accessibility. As an economic research organization, we are equally focused on uncovering both the patient-level outcomes and the measurable financial benefits VMS+™ technology can deliver—ensuring that innovation improves care while strengthening the economic sustainability of healthcare systems.” Dana Friesen brings over 15 years of experience in financial analysis and ROI optimization within the medical device and healthcare sectors. Summit Sciences specializes in delivering

transformational insights and solutions to clients, enabling them to translate complex data into actionable business strategies.

This engagement is part of Ventripoint’s broader strategy to accelerate market adoption of its VMS+ platform, which uses artificial intelligence to generate accurate 3D models of the heart from standard 2D ultrasound images, offering a faster, more affordable and accessible alternative to traditional MRI scans.

About Ventripoint Diagnostics Ltd.

About Summit Sciences

Over the past two decades Summit Sciences has worked with numerous clinical agencies and delivered billions in lifetime partner savings. Summit’s research services provide hospitals, manufacturers, and healthcare organizations with the critical data needed to make informed decisions about technology adoption, implementation strategies, and performance optimization.

Summit employs advanced research methodologies combining clinical outcome analysis, operational efficiency metrics, and financial impact assessment to deliver actionable insights that improve patient care while optimizing resource utilization and demonstrating clear return on investment.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Ventripoint Unveils a Global Model for A.I.- Enhanced Heart Care Through Partnership With the Nisg̱a’a Valley Health Authority

New care delivery model to provide advanced cardiac imaging to remote and Indigenous communities in British Columbia, across Canada, and worldwide.

Toronto, Ontario (December 12, 2025) – Ventripoint Diagnostics Ltd. (” Ventripoint “, “ VPT ” or the ” Company “), (TSXV:VPT; OTC:VPTDF) a leader in AI-enhanced cardiac imaging solutions, is proud to announce a transformative partnership with Nisg̱ a’a Valley Health Authority (NVHA) that is the next step towards forming a groundbreaking new model for delivering accessible, high-quality heart care powered by artificial intelligence.

The new model follows a “hub-and-spoke” design, where a central hub with advanced cardiac capabilities provides support to connected sites in smaller, remote, and Indigenous communities.

Local healthcare providers can acquire, enhance and read ultrasound scans using VMS+™ and transmit them digitally as needed to specialists at the hub for rapid interpretation and consultation.

The Nisg̱ a’a Valley Health Authority will serve as the first remote site in this expanding network, and will be linked to a regional centre with tertiary and quaternary care capabilities. Future phases are intended to include:

● Additional First Nations communities in British Columbia and all of Canada ● Arctic regions across the country

● Rural and northern communities worldwide

● Communities in the Amazon, Africa, India, and other regions where MRI access is limited This expected results of the model are simple yet profound: delivering advanced cardiac imaging directly to patients – Indigenous and non-Indigenous – without the need for long-distance travel, high costs, or extended wait times.

At the core of this model is Ventripoint’s VMS+™ system, which delivers MRI-level heart measurement accuracy by transforming standard 2D echocardiograms into 3D volumetric images. This technology enables precise cardiac assessments to be performed at the point of care, reducing costs and eliminating the need for time-consuming MRI scans. The system is already being used to support diagnosis and monitoring of indications such as congenital heart disease, post-surgical recovery, chemotherapy-related cardiac complications, pulmonary hypertension, heart failure, and valve dysfunction.

“Ventripoint is a made-in-Canada innovation already in use across Canada, the United States, Europe, and the United Kingdom,” said Hugh MacNaught, CEO of Ventripoint. “Through our collaboration with the Nisg̱ a’a Valley Health Authority, we are creating a scalable model of heart

care that can extend from the Arctic to the Amazon, ensuring that everyone, regardless of geography, has access to advanced diagnostics.”

Corinne McKay, CEO, Nisga’a Valley Health Authority, said: “Our responsibility is to ensure that every Nisga’a citizen – wherever they live – has access to the highest standard of care, no matter where they live here in the Nass or urban centers of Terrace or Vancouver. Partnering with Ventripoint allows us to explore innovative tools that support more accurate diagnoses, faster treatment decisions, and truly patient-centred care right here at home. For NVHA, this collaboration is about more than technology; it is about advancing health sovereignty for the Nisga’a people and strengthening our ability to serve our people with excellence, compassion, and cultural integrity.”

Ventripoint plans to expand this model throughout Canada and internationally, advancing the goal of universal access to affordable, accurate cardiac diagnostics.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+™ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Nisg̱ a’a Valley Health Authority

The Nisg̱ a’a Valley Health Authority (NVHA) is the first fully accredited First Nations health authority in British Columbia and a cornerstone of health and wellness for the Nisg̱ a’a people.

Established in 1984, NVHA provides culturally grounded, community-led health services to Nisg̱ a’a citizens throughout the Nass Valley and in urban centres such as Prince Rupert, Terrace and Vancouver. NVHA integrates modern medical practices with Nisg̱ a’a cultural knowledge and values, offering programs in primary care, mental health, chronic disease management, maternal and child health, crisis response, and community wellness. The organization continues to expand its services and advance the health sovereignty of the Nisg̱ a’a – honouring the past while building a healthier future for generations to come.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Ventripoint Diagnostics Announces Appointment of David Swetlow as Chief Financial Officer

New CFO appointment strengthens Ventripoint’s leadership team and supports global rollout of AI-powered VMS+™ cardiac imaging platform.

Toronto, Ontario (December 3, 2025) – Ventripoint Diagnostics Ltd. (” Ventripoint “, “ VPT ” or the ” Company “), (TSXV:VPT; OTC:VPTDF) a leader in AI-enhanced cardiac imaging solutions, today announced the appointment of David Swetlow, CPA, CA, iGP as Chief Financial Officer (“ CFO ”), effective immediately. This appointment represents an important step in strengthening Ventripoint’s leadership team as the Company embarks on its new commercial strategic vision and transitions into its growth phase.

Mr. Swetlow brings extensive senior management, financial and public company leadership experience from various roles across high-growth medical technology and innovative life science companies, including Sernova, Ondine, Protox, HealthPricer, One Person Health, QLT and Xillix, with a track record of building and executing robust capital markets strategies; company scale up, product launch and commercialization strategies success; driving and evolving financial systems, reporting, and operational performance for next stage growth; strategic relationship management; and enhancing corporate governance. His broad expertise will be instrumental to positioning VPT to achieve the next stage of VMS+ platform market adoption success and expansion abroad.

“This is a pivotal moment for Ventripoint,” said Hugh MacNaught, President & CEO of Ventripoint Diagnostics. “David’s leadership will play a vital role as we execute on a refreshed commercial strategy designed to scale our technology and platform, strengthen our global partnerships, and position the company for new markets and revenue growth.

As Ventripoint moves into this next stage, the Company also extends its appreciation to Jimmy Jeon, who has resigned as CFO and Marelli Services for their valuable support to date. Their contributions have helped provide stability and continuity through a period of important transition.

As CFO, Mr. Swetlow will oversee financial strategy, capital markets, financial reporting and operations, working closely with the executive team and Board of Directors as VPT advances commercialization efforts in the U.S., Canada, Europe, the UK, and other priority markets.

“The VMS+™ technology platform stands at the forefront of cardiac imaging innovation, harnessing and leveraging the convergence of AI with imaging diagnostics to enable what hasn’t previously been readily accomplishable cost effectively in the healthcare ecosystem, nor in a near to real-time manner to enhance care and reduce the anxious wait times for at-risk cardiac patients to find out further answers” said Mr. Swetlow. “I am excited to join Ventripoint at this critical juncture to evolve the financial and commercial foundations needed to scale and make this technology globally available for current and expanded indications.”

This appointment represents another foundational step in building a high-performance leadership team capable of guiding VPT through its scale up phase. With a renewed commercial focus and a rapidly growing global interest in the Company’s VMS+ cardiac imaging solution, the addition of an experienced public company life sciences industry CFO strengthens Ventripoint’s ability to deliver on its strategic priorities and realize on opportunities ahead.

The Board of Directors has awarded Mr. Swetlow 1,000,000 options exercisable at $0.11 with a term of 10 years and vesting over 12 months.

In other news, the Company wishes to correct the news release of September 3, 2025 as the insider reported to have invested $105,000 has been determined not to be an insider of the company.

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+™ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Ventripoint Diagnostics and Providence Health Care Ventures Announce Collaboration to Validate AI-Enabled Cardiac Imaging at St. Paul’s Hospital

Study to evaluate potential to reduce cardiac MRI demand and expand access to advanced heart diagnostics across care settings

Toronto, Ontario (October 29, 2025) – Ventripoint Diagnostics Ltd. (” Ventripoint ” or the ” Company “), (TSXV:VPT; OTC:VPTDF) today announced it has entered into a collaboration with Providence Health Care Ventures (“PHC Ventures”) to validate the Company’s VMS+™ platform at St. Paul’s Hospital in Vancouver, British Columbia. The collaboration will evaluate how artificial intelligence-enhanced echocardiography may reduce dependence on cardiac MRI by providing accurate cardiac measurements earlier in the diagnostic pathway, with the potential for a subset of patients to avoid MRI entirely.

Cardiac MRI is widely regarded as the gold standard for accurate heart volume and function measurements, but limited availability and long wait times can delay treatment decisions. VMS+™ uses artificial intelligence to generate 3-D heart models from standard 2-D echocardiography images and has demonstrated clinical agreement with MRI-derived measurements in previously published evaluations. The platform is FDA-cleared and Health Canada-licensed and operates on existing 2D ultrasound systems, allowing health systems to increase advanced imaging capacity without capital acquisition of new scanners.

Building on Prior Clinical Evidence

VMS+™ has been implemented at sites including the Hospital for Sick Children (Toronto), the Peter Munk Cardiac Centre (University Health Network, Toronto) and evaluated in clinical studies at Mayo Clinic, where echo-derived measurements using VMS+™ were shown to closely align with cardiac MRI. A poster recently presented at the British Society of Echocardiography 2025 conference demonstrated that VMS+™ used for longitudinal assessment of adult congenital heart defect patients generated results comparable to MRI and more accurate than 3D echocardiography.

The collaboration with PHC Ventures aims to validate VMS+™ performance within real-world workflows at St. Paul’s Hospital – one of Western Canada’s leading cardiac programs – by comparing VMS+™ derived measurements from echocardiography with cardiac MRI, and by evaluating workflow integration, potential reductions in MRI referrals, impact on wait times, and associated system-level cost efficiencies.

“This technology helps identify which patients truly need an MRI and which can be safely assessed using a standard echocardiogram,” said Brian Simmers, President of PHC Ventures.

“By doing so, we can reduce MRI wait times, lower costs, and provide faster access to high-quality cardiac care.”

“MRI remains the gold standard for cardiac imaging, but it is not always within reach for every patient,” said Dr. Robert Moss, Physician Lead, Echocardiography, St. Paul’s Hospital. “The promise of AI-enhanced echocardiography like VMS+™ is that it could bring MRI-level precision to a more accessible modality. That means faster diagnoses, more timely treatment decisions, and improved patient outcomes — especially in communities where access to advanced imaging is limited.”

Enabling Access Beyond Major Centres

By augmenting conventional ultrasound infrastructure, VMS+™ has the potential to extend advanced cardiac diagnostics to rural and Indigenous communities, where MRI access is constrained and patient travel distances are significant. AI-enhanced echocardiography at the point-of-care may reduce avoidable transfers, support ongoing monitoring in local settings, and contribute to more equitable access to advanced imaging.

“Our vision is to make high-quality cardiac imaging available wherever an echo machine exists,” said Hugh MacNaught, President and CEO of Ventripoint. “Partnering with PHC Ventures and the St. Paul’s cardiac team enables validation in a leading cardiac centre and creates a pathway to demonstrate health-system impact across settings – from tertiary hospitals to remote communities.”

The collaboration is expected to commence in November 2025, with implementation beginning in early 2026.

About Ventripoint Diagnostics Ltd.

About Providence Health Care Ventures

PHC Ventures is the commercialization arm of Providence Health Care. The group enables the validation and deployment of health innovations by providing access to clinical environments, domain expertise, and collaboration within Providence’s hospital network, including St. Paul’s Hospital and the new Clinical Support and Research Centre.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

Ventripoint Provides Corporate Update and Announces Shareholder Teleconference

Toronto, Canada — October 24, 2025 — Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”), (TSXV:VPT; OTC:VPTDF), a leading provider of innovative cardiac diagnostic solutions, is pleased to provide a shareholder update.

Dear Shareholders ,

We are pleased to provide this update on advancements at Ventripoint and to express our ongoing appreciation for your support. Since our last update the Ventripoint team has continued to build a foundation for commercializing VMS+™ and advancing the company towards growth. The business plan and budget have been updated and management is currently pursuing suOicient capital to enable proper execution of the plan.

Business Plan

Following the regulatory clearance/approval of the latest version of VMS+™ our attention is now directed towards evolving the user base from research applications to routine clinical adoption.

An important early step is the upgrade of existing sites to VMS+™ V4 to ensure that users benefit from improvements to the system, and that there is a high degree of consistency in user experience. Because certain sites are engaged in research projects, upgrades for those sites are delayed until the completion of their studies.

Ventripoint was founded to create an alternative method of imaging young Congenital Heart Defect (“CHD”) patients and since then has received recognition of the accuracy of the VMS+™ system, particularly for measurement of the right ventricle. We continue to work towards positioning Ventripoint as the market leader for the CHD segment while establishing higher awareness of the applicability of the system to additional indications where RV measurements are needed and greater accuracy in measurement of all four heart chambers is desired.

Despite VMS+™ being cited in approximately 60 publications to date there is an ongoing need to generate supporting data and results. The plan includes objectives to update the evidence

base from earlier studies to more current validation and real-world evidence demonstrating the clinical and financial benefits of the system.

To date Ventripoint has made considerable investment in innovation as it relates to product development. Attention is now turning to engaging healthcare partners in clinical innovation, where implementation of VMS+™ can provide greater accessibility with faster, accurate results that contribute to improved patient outcomes.

An important element of the plan is the evolution of the business and revenue models and improvements of the sales process to reduce friction while shortening the sales cycle.

Commercialization

We are in the process of expanding the commercial team to drive sales and growth. Several capable and experienced candidates have been identified and engaged on a consulting basis with the expectation of transitioning them to full-time roles once suOicient capital has been raised.

Marketing

We have evolved the marketing function to include processes for characterizing market need prior to committing capital to new product development and to better align sales and marketing resources to addressing these needs. The Ventripoint team is actively engaging customers and users in focused discussions that are generating valuable insights that will help to ensure optimal product-use fit.

Interviews with users at those sites that have upgraded identify higher satisfaction and an improved user experience. We expect that these sites will see opportunities for innovation that provide workflow eOiciencies, greater diagnostic confidence, and significant reductions in the need for secondary imaging (notably cardiac MRI), which traditionally presents scheduling, cost, and patient compliance challenges. These advancements provide the ability to integrate VMS+ into routine care pathways for longitudinal monitoring.

With the emergence of new devices and treatments for valve dysfunction there is growing recognition of the benefits of earlier diagnosis, treatment and intervention. With the support of an industry advisor the team has achieved considerable progress in establishing contact with KOLs, gaining insights, and identifying where VMS+™ may be positioned to enable improved patient outcomes. The heart valve repair and replacement market is estimated to be approximately $9B in 2024 with a CAGR of 10% through 2034.

As in 2024 we are participating in a select number of trade shows and conferences.

Ventripoint participated in the AEPC meeting in Hamburg in May, and the ACHD meeting in Toronto in June and is a sponsor of the annual Ollie Hinkel Heart Foundation meeting.

We are placing a stronger focus on customer training, installation, and support, especially concerning connectivity and clinical integration. Our marketing team is creating training videos which are available to users, and that will improve the customer experience.

Sales Process

Following the addition of Karl Pringle to the Ventripoint team the sales function and processes have been reviewed and updated. The business plan now reflects a Device-as-a-Service (“DaaS”) subscription model which we believe will reduce friction in the sales cycle while creating a growing base of recurring revenue. Proposals featuring the DaaS subscription have been presented to potential customers.

During the past year the commercial team has worked on implementation of a CRM which is now in place and being integrated into the sales process. We are encouraged to note that the number of qualified leads from Europe and North America is increasing.

To date the sales process followed a traditional model based on on-site product demonstrations to multiple staO members. These demonstrations are challenging to schedule due to customer availability and incur travel expenses for Ventripoint team members. We are working towards establishing virtual pre-sale demonstrations and restricting on-site visits to installation, training and validation to shorten the sales cycle and reduce expense.

In Europe and the U.K. we are in the process of developing new approaches to demonstrations and support that will be responsive and aOordable.

Our European distributor AngioPro has recommitted to working with Ventripoint and invested in the Company. We are working with AngioPro to recruit a EU-based applications specialist to perform on-site product demonstrations and training. The new program will be initiated on November 1 st .

The American market has been highlighted as a key region for the Company. The team is engaging directly with healthcare providers in the U.S. to validate the sales model and process prior to expansion through specialty distributors in 2027.

Congenital Heart Defect Program

Shortly after joining Ventripoint as Director of the CHD program Thomas Brown faced changing circumstances and tendered his resignation. However, this notice was provided with an introduction to an industry veteran who has accepted the role and is now actively working with the company.

Virginia-based Joe Hostetter was trained in sonography and has enjoyed a successful career in marketing and sales positions with companies including Siemens, Toshiba (now Canon),

GE and Intelligent Ultrasound. In his new role Joe will work with the commercial team to update and execute the CHD program. His orientation includes introductions to our partners at ASCEND Cardiovascular the OHHF. Proposals have been presented to hospitals in the U.S.

At the recent BSE 2025 conference Dario Freitas, lead for the ACHD echocardiography service at Guy’s and St Thomas’ hospitals in London, UK presented a poster summarizing the results from a multi-year study on adult CHD patients that showed accuracy comparable to cMRI and superior to 3D echocardiography. The amalgamation of the Royal Brompton Hospital and Harefield Hospital with the Guy’s and St Thomas’ NHS Foundation Trust, make up the largest specialist heart and lung centre in the UK and among the largest in Europe.

Business Development and Partnerships

ASCEND Cardiovascular

In Q4 2024 it was announced that we are working with ASCEND to create a license agreement for the integration of VMS+™ 3D capabilities directly into the Ascend technology stack. Since then the development teams from both companies have engaged in numerous meetings to define the development plan which is close to being completed.

Simultaneously, the commercial teams have engaged in regular meetings and are collaborating on a campaign focused on pediatric centers. ASCEND will shortly launch a newsletter and awareness campaign that highlights the relationship with Ventripoint and the benefits of VMS+™.

Ollie Hinkle Heart Foundation

We continue to collaborate with OHHF, who are introducing us to potential customers and supporters.

China

Further to the announced term sheet with Lishman Global, progress has continued towards finalizing the license, execution of which is contingent on an equity investment into Ventripoint. In the meantime, Lishman has purchased components to complete the manufacture of 10 integrated systems which will be used for development, demonstration and regulatory purposes. Ventripoint is providing an application specialist for on-site support, the expense of which is being underwritten by Lishman. Initial reports from the visit are positive.

India

We continue to engage with an India-based family oOice to pursue distribution, joint ventures, manufacturing, and financial opportunities in South Asia. With its large

population, improving living standards, and growing healthcare needs, this region is an ideal fit for VMS+™. We have received enquiries regarding other Asian markets and are qualifying these against our business plan and objectives.

Additionally, Ventripoint engaged Dr. Muthu Singaram as a business advisor to assist with introductions to additional potential business, technology, clinical and financial partners in South Asia and the United States. Muthu was recently appointed Senior Fellow at the Babson College Kerry Murphy Healey Center for Health Innovation and Entrepreneurship.

For the second year in a row, Babson College was recently ranked the No. 2 Best College in America by The Wall Street Journal according to the WSJ/College Pulse 2026 Best Colleges in the U.S. report.

Summit Sciences

Ventripoint recently engaged Dana Friesen, CEO of Summit Sciences, to provide leadership on developing an advanced analysis of customer ROI for implementation of VMS+™. Working with his team of experts at Summit and academic thought leaders, Dana is developing a pilot program that will model VMS+™ impact on patient outcomes and the anticipated savings enabled through the use of the system.

Manufacturing, Technology and Product Development Building on the successful development of VMS+ v3.2, (featured our groundbreaking magnet-free sensors) and VMS+™ v4.0 (featuring software automation) followed by regulatory approvals attention has been devoted to manufacturing and product life cycle management.

The production process for the new magnet-free sensors has been upgraded with the quality and performance standards now being met or exceeded. An order has been placed for a quantity of components suOicient to build 25 VMS+™ systems.

During the current year our team has continued to achieve successful quality and manufacturing audits which highlight their dedication and expertise.

Ongoing development activities will be focused on improving integration into clinical workflow, increased automation, and new functionality as identified by marketing-led user insight initiatives.

Finance

During the past year we have closed a number of private placements to support our growth and commercialization eOorts. These were structured to leverage commitments from our team and insiders while avoiding unnecessary dilution. These financings, coupled with careful management of expenses enabled the Company to complete development and

secure approval for VMS+™ updates, maintain operations and a basic level of marketing and sales activities. Ventripoint is focused more directly on sales and growth, which is dependent on securing growth capital.

We are continuing to work with investment bankers to secure capital, and marketing groups to increase awareness of the company and investment opportunity. Capital markets remain challenging and this year to date have been aOected by historically unusual events. We remain optimistic of increased interest in Ventripoint and recognition by investors of the window of opportunity created by growing clinical need. We continue to evaluate strategic non-dilutive funding opportunities, including potential clinical collaborations and licensing partnerships.

Strategic Priorities – 2025 and Beyond

We are excited to be moving ahead with a substantially improved product that will contribute to better healthcare outcomes for the millions of people suOering heart defects, diseases and disorders.

Our plan for success is focused on four key value drivers:

• Achieving Commercial Traction: Our sales outreach is targeting high-volume echo labs and cardiac centers of excellence.

• Supporting Clinical Innovation: We will work with clinical partners to demonstrate the value of VMS+™ in a number of use cases for both right and left heart pathologies, and in a variety of clinical settings.

• Developing More Compelling ROI Models: We believe that adoption of VMS+™ should result in savings that eclipse the returns illustrated through traditional models based on procedure volume and reimbursement.

• Enhancing Platform Capabilities: We will continue investment into refining our AI, increasing automation, and creating novel analytics that contribute to enhanced clinical workflow.

• Pursuing Strategic Collaborations: We continue to actively seek engagement with industry partners for joint development, co-marketing, and potential channel distribution.

Shareholder Teleconference

The Company wishes to invite its shareholders to a videoconference to be held on October 30 th , 2025 at 1 pm EST. Dial-in numbers are listed below.

Closing Comments

We have emerged from a very challenging year with an updated and enhanced product and a new commercialization plan. Timely and complete execution of this plan is dependent on securing growth capital which we are diligently pursuing. The underlying market drivers for accurate, reproducible, and scalable cardiac imaging remain compelling and VMS+™ is well positioned to capitalize on these trends. The entire Ventripoint team is committed to the Company’s success and we thank you for your continued support and for taking the time to read this update.

Sincerely,

Hugh MacNaught

President and CEO hmacnaught@ventripoint.com

(604) 671-4201

Zoom Meeting on Thursday, October 30 th at 1pm EST.

Link

Join Zoom Meeting https://us02web.zoom.us/j/89501844900?pwd=092dGQ8T2xZzjxAIdkjhpjKbdtpPFF.1 Meeting ID: 895 0184 4900

Passcode: 095932

One tap mobile

+14388097799,,89501844900#,,,,*095932#

+15873281099,,89501844900#,,,,*095932#

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This aOordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard

for all Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

Forward Looking Statements

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could diOer materially from those currently anticipated due to several factors and risks. Factors which could materially aOect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint Announces Extension and Up Size of Non-Brokered Convertible Debenture Unit Private Placement

Toronto, Ontario, October 3, 2025 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces that it will seek approval of TSX Venture Exchange (“ TSXV ” or the “ Exchange ”) to extend its previously announced non-brokered private placement (“ Offering ”) of unsecured convertible debentures (“ Debentures ”) to November 2, 2025. (See press releases dated August 26, 2025 and September 3, 2025).

Ventripoint also announces that it will seek approval of the TSXV to increase the size of the Offering from $500,000 to $560,000.

Each Unit is comprised: of one (1) unsecured convertible debenture principal amount of $1,000 (“ Debentures ”) convertible into common shares (“ Common Shares ”) of the Corporation; and 9,000 common share purchase warrants (“ Warrants ”).

The Debentures are convertible into Common Shares of the Corporation at the option of the holder at any time prior to maturity at a conversion price of $0.11 per Common Share (the “ Conversion Price ”). Each whole Warrant will entitle the holder thereof to purchase one (1) Common Share at a price of $0.14 until December 31, 2027.

The Debentures mature December 31, 2027 and bear interest at the rate of ten per cent (10%) payable semi-annually in arrears in either cash or at the option of the Corporation by issuance of Common Shares at a 20-day VWAP market price, determined at time of payment, subject to Exchange approval.

The Corporation will use the proceeds of the Offering to fund operational costs related sales and marketing, additional key personnel, and general working capital purposes.

All securities issued and issuable pursuant to the Offering are subject to a hold period of four months plus one day from the date of closing of the Offering. The Offering is subject to final approval by the Exchange.

About Ventripoint Diagnostics Ltd.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Ventripoint Announces Successful Completion of Key Quality Audits

Toronto, Ontario (September 19, 2024) – Ventripoint Diagnostics Ltd. (” Ventripoint ” or the ” Company “), (TSXV:VPT; OTC:VPTDF) is pleased to announce the successful completion of its annual audit under the Medical Device Single Audit Program (MDSAP), ISO 13485 Quality Management System, and EU Medical Device Regulation (MDR) requirements by Notified Body.

The audit resulted in zero major nonconformities and confirmed Ventripoint Diagnostics Ltd.’s continued compliance with global quality and regulatory standards.

This achievement reflects Ventripoint’s ongoing commitment to delivering safe, effective, and high-quality medical devices to patients worldwide. It also reinforces the company’s strong quality culture and dedication to meeting the evolving regulatory requirements across multiple jurisdictions. The audits addressed:

MDSAP (Medical Device Single Audit Process): The MDSAP audit, conducted by a third-party auditing organization, ensures compliance with the medical device regulatory requirements of multiple jurisdictions, including the U.S. and Canada. This program streamlines the regulatory process, allowing Ventripoint to maintain certifications across these key markets efficiently.

ISO 13485:2016 Certification: ISO 13485:2016 is the globally recognized standard for quality management systems specific to the medical device industry. Passing this audit validates our comprehensive quality system, ensuring consistent performance, safety, and product quality.

MDR 2017/745: The successful audit under the European Union’s MDR 2017/745 demonstrates that Ventripoint’s products meet the rigorous new regulatory standards governing medical devices in the European market. This regulation focuses on patient safety, product traceability, and post-market surveillance, ensuring a high level of safety and performance for all medical devices sold in Europe.

“We are pleased to share that Ventripoint’s dedication to maintaining a robust quality management system and ensuring that its products meet the stringent requirements of key international regulatory bodies is again reflected by a successful audit. This is an important aspect of our business that provides assurance to healthcare providers, patients and payors” said Ventripoint President and CEO, Hugh MacNaught. “The audit demonstrated that the advancements incorporated into VMS+4.0 were effectively managed within our quality system and provides confidence our team and processes will continue to meet the needs of our ongoing development and manufacturing programs.”

About Ventripoint Diagnostics Ltd.

Ventripoint is an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary Knowledge Based

Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.

For further information, please contact:

Hugh MacNaught hmacnaught@ventripoint.com

604-671-4201

Forward Looking Statements

About VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) is a Toronto-based medical device company that has developed and commercialised the VMS+ — an FDA-cleared, AI-powered cardiac imaging system that transforms standard 2D ultrasound scans into high-fidelity 3D models of all four cardiac chambers, with measurement accuracy equivalent to a cardiac MRI. Using the company’s patented Knowledge Based Reconstruction (KBR) artificial intelligence, the VMS+ system attaches to any existing standard ultrasound machine, produces actionable 3D cardiac models within minutes, and critically, does not require perfect image quality — removing a key barrier to deployment in community hospitals and developing healthcare settings. VentriPoint is the first and only cost-effective diagnostic tool capable of measuring volume and function across all four cardiac chambers, including the notoriously difficult right ventricle.

The company is commercially active in Europe, the United Kingdom, the United States, and Canada, with VMS+ deployed at major hospital systems in each region. Revenue grew approximately 94% year-over-year in FY2024 — albeit from an early base — demonstrating accelerating market traction. Clinical applications span congenital heart disease, pulmonary hypertension, heart failure, pregnancy-related cardiac conditions, and cardiotoxicity monitoring in oncology patients. VentriPoint launched its VMS+ 4.0 system with an associated whitepaper (March 2025) demonstrating improved AI performance, and in late 2025 announced a study to evaluate VMS+ potential to reduce cardiac MRI demand across diverse care settings — a potential precursor to standard-of-care designation in key markets.

Market Need, and the MRI Access Gap

VentriPoint’s mission is to democratize access to high-accuracy whole-heart imaging by bridging the diagnostic gap between conventional echocardiography and cardiac MRI. Cardiovascular disease is the leading global cause of death, responsible for approximately 17.9 million deaths annually (WHO, 2023), yet access to the gold-standard cardiac MRI remains severely constrained by cost (US$1,000–3,000 per scan), scanner availability, examination time (45–90 minutes), and technical expertise requirements. Standard 2D echocardiography is widely available but lacks volumetric accuracy across all four chambers — particularly the right ventricle. VMS+ bridges this gap precisely: it generates 3D volumetric measurements and ejection fractions for all four chambers from standard ultrasound data, within minutes, at echo cost, and without requiring specialized hardware or perfect imaging conditions. The addressable market encompasses the entire global installed base of cardiac ultrasound systems — estimated in the hundreds of thousands of units worldwide — within a global ultrasound market projected to grow from US$7.8 billion (2021) to US$12.9 billion by 2028 (ventripoint.com, Investors Overview).

Technology, Clinical Validation, and VMS+ 4.0

VentriPoint’s KBR technology uses a proprietary AI model trained on a large database of cardiac MRI and echocardiographic images to reconstruct 3D cardiac models from conventional 2D echo data — functioning with standard 2D probes rather than requiring expensive 3D echo equipment. The VMS+ 4.0 system, released in 2025, demonstrates clinically significant improvements in measurement accuracy and reproducibility versus the prior generation, as documented in a peer-reviewed whitepaper published March 2025 (ventripoint.com). The technology has been clinically validated at major academic centers including the Deutsches Herzzentrum Berlin (DHZC), where Prof. Felix Berger, Director of the Clinic for Congenital Heart Disease and Pediatric Cardiology, described VMS+ as providing a precise spatial view of complex congenital malformations that enables more precise therapy planning and monitoring. Multiple peer-reviewed publications support the technology’s clinical evidence base across several disease indications.

Commercial Traction and Key Partnerships

VentriPoint’s commercial deployment spans major hospital systems in Europe, the UK, the U.S., and Canada, validating the technology’s cross-regulatory and cross-cultural applicability. Key commercial relationships include the Ollie Hinkle Heart Foundation, which has committed to introducing VentriPoint to all of its hospital partners with the stated goal of making VMS+ a standard of care, and ASCEND, whose CEO Jeffrey Soble has endorsed VMS+ as a reliable and effective tool for clinicians at global scale (ventripoint.com, Testimonials). FY2024 revenue of approximately C$95,172 represented 94% year-over-year growth from C$49,183 in FY2023, demonstrating genuine market adoption acceleration. At a current market capitalization of approximately C$19 million (Investing.com, March 2026), VentriPoint trades at a deeply compressed valuation relative to commercial-stage medtech peers with FDA clearance and international hospital deployments.

MRI Substitution Study and High-Value Clinical Niches

VentriPoint’s most strategically significant near-term development is its formal study to evaluate VMS+ potential to reduce cardiac MRI demand across diverse care settings (announced late 2025, ventripoint.com). If successful, this study opens high-value commercial pathways including formal inclusion in clinical practice guidelines, reimbursement code eligibility in the U.S., Canada, and EU, and enterprise procurement by major integrated health systems seeking to reduce imaging backlogs and per-procedure costs. Beyond standard cardiology, VentriPoint has developed high-value niche applications in congenital heart disease — where right ventricular assessment is especially critical and where the Ollie Hinkle Foundation relationship provides direct access to CHD patients — and in cardiotoxicity monitoring for oncology patients, a rapidly growing population requiring frequent cardiac assessment as cancer survival rates improve.

Key Milestones and Investment Summary

VentriPoint’s key milestones include: FDA clearance and Health Canada approval of VMS+; international hospital deployments across four major markets; VMS+ 4.0 launch with peer-reviewed whitepaper demonstrating improved AI performance; ~94% year-over-year revenue growth in FY2024; and launch of the formal MRI substitution study. Near-term catalysts include interim MRI substitution study results, new hospital deployment announcements, potential reimbursement code submissions in key markets, and additional peer-reviewed publications. VentriPoint represents a high-risk, high-reward opportunity: an FDA-cleared, clinically validated medical AI platform with international traction and accelerating revenue, trading at approximately C$19 million market capitalization — a valuation that appears deeply compressed against the structural scale of the cardiovascular diagnostics market and the company’s demonstrated technological and clinical advantages.

EXCHANGE:
TSXV
Symbol: VPT

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decisions. This is a paid advertisement and is neither an offer nor a recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc.

While the information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful; investing in securities carries a high degree of risk; you may likely lose some or all of your investment.

ABOUT US

Equity Insider offers news and information from global equity markets. We focus on emerging markets, along with hot topics and timely business news.

POPULAR

Alibaba (NYSE:BABA) Stock After Recent Slide Is The Market Pricing In Too Much Caution

Q1 Earnings Outperformers: C3.ai (NYSE:AI) And The Rest Of The Data Infrastructure Stocks

Equity Insider